Ischemic Stroke and Vaccine-Induced Immune Thrombotic Thrombocytopenia following COVID-19 Vaccine: A Case Report with Systematic Review of the Literature

被引:13
|
作者
Rizzo, Angelo Cascio [1 ]
Giussani, Giuditta [1 ]
Agostoni, Elio Clemente [1 ]
机构
[1] ASST Grande Osped Metropolitano Niguarda, Neurol & Stroke Unit, Milan, Italy
关键词
Stroke; Vaccine-induced immune thrombotic thrombocytopenia; COVID-19; vaccine; Large vessel occlusion; Thrombotic thrombocytopenia;
D O I
10.1159/000524290
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic syndrome observed after adenoviral vector-based vaccines for severe acute respiratory syndrome coronavirus 2. It is characterized by thrombocytopenia, systemic activation of coagulation, extensive venous thrombosis, and anti-platelet factor 4 antibodies. Arterial thrombosis is less common and mainly affects the aorta, peripheral arteries, heart, and brain. Several cases of ischemic stroke have been reported in VITT, often associated with large vessel occlusion (LVO). Here, we describe a case of ischemic stroke with LVO after Ad26.COV2.S vaccine, then we systematically reviewed the published cases of ischemic stroke and VITT following COVID-19 vaccination. Methods: We describe a 58-year-old woman who developed a thrombotic thrombocytopenia syndrome with extensive splanchnic vein thrombosis and ischemic stroke due to right middle cerebral artery (MCA) occlusion, 13 days after receiving Ad26.COV2.S vaccination. Then, we performed a systematic review of the literature until December 3, 2021 using PubMed and EMBASE databases. The following keywords were used: ( "COVID-19 vaccine ") AND ( "stroke "), ( "COVID-19 vaccine ") AND ( "thrombotic thrombocytopenia "). We have selected all cases of ischemic stroke in VITT. Results: Our study included 24 patients. The majority of the patients were females (79.2%) and younger than 60 years of age (median age 45.5 years). Almost all patients (96%) received the first dose of an adenoviral vector-based vaccine. Ischemic stroke was the presenting symptom in 18 patients (75%). Splanchnic venous thrombosis was found in 10 patients, and cerebral venous thrombosis in 5 patients (21%). Most patients (87.5%) had an anterior circulation stroke, mainly involving MCA. Seventeen patients (71%) had an intracranial LVO. We found a high prevalence of large intraluminal thrombi (7 patients) and free-floating thrombus (3 patients) in extracranial vessels, such as the carotid artery, in the absence of underlying atherosclerotic disease. Acute reperfusion therapy was performed in 7 of the 17 patients with LVO (41%). One patient with a normal platelet count underwent intravenous thrombolysis with alteplase, while 6 patients underwent mechanical thrombectomy. A malignant infarct occurred in 9 patients and decompressive hemicraniectomy was performed in 7 patients. Five patients died (21%). Conclusion: Our study points out that, in addition to cerebral venous thrombosis, adenoviral vector-based vaccines also appear to have a cerebral arterial thrombotic risk, and clinicians should be aware that ischemic stroke with LVO, although rare, could represent a clinical presentation of VITT.
引用
收藏
页码:722 / 734
页数:13
相关论文
共 50 条
  • [11] A probable case of vaccine-induced immune thrombotic thrombocytopenia secondary to Pfizer Comirnaty COVID-19 vaccine
    Goh, Carol C. Y.
    Keat, Chew Teng
    Kien, Chiang Su
    Sim, Goh Ai
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2022, 52 (02): : 113 - 116
  • [12] COVID-19 vaccine safety surveillance and emerging concerns of vaccine-induced immune thrombotic thrombocytopenia
    Shyh Poh Teo
    Journal of Geriatric Cardiology, 2021, 18 (11) : 952 - 956
  • [13] COVID-19 vaccine safety surveillance and emerging concerns of vaccine-induced immune thrombotic thrombocytopenia
    Shyh Poh Teo
    Journal of Geriatric Cardiology, 2021, 18 (11) : 952 - 956
  • [14] COVID-19 vaccine safety surveillance and emerging concerns of vaccine-induced immune thrombotic thrombocytopenia
    Teo, Shyh Poh
    JOURNAL OF GERIATRIC CARDIOLOGY, 2021, 18 (11) : 952 - 956
  • [15] Adrenal haemorrhage and COVID-19 vaccine-induced immune thrombotic thrombocytopenia: correspondence
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2022, 115 (12) : 875 - 875
  • [16] Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia
    Garnier, Matthieu
    Curado, Adelya
    Billoir, Paul
    Barbay, Virginie
    Demeyere, Matthieu
    Dacher, Jean-Nicolas
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2021, 102 (10) : 649 - 650
  • [17] Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia
    Favaloro, Emmanuel J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (04) : 559 - 570
  • [18] COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review of the potential mechanisms and proposed management
    Alam, Walid
    SCIENCE PROGRESS, 2021, 104 (02)
  • [19] COVID-19 vaccine-induced myocarditis: Case report with literature review
    Nassar, Mahmoud
    Nso, Nso
    Gonzalez, Carlos
    Lakhdar, Sofia
    Alshamam, Mohsen
    Elshafey, Mohammed
    Abdalazeem, Yousef
    Nyein, Andrew
    Punzalan, Benjamin
    Durrance, Richard Jesse
    Alfishawy, Mostafa
    Bakshi, Sanjiv
    Rizzo, Vincent
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (05)
  • [20] Vaccine-Induced Thrombotic Thrombocytopenia: A Case Report
    Silva, Luciana
    Pombal, Rita
    Fidalgo, Mariana
    Freitas, Andreia
    Barbosa, Manuel
    Magalhaes, Luisa
    Correia, Margarida
    Valente, Joao
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)